Johnson & Johnson (JNJ) has been facing fluctuating market trends recently, as seen through various gains and losses in share holdings. The company has been hit with an $8M verdict in a Mesothelioma Talc Lawsuit yet continues with its expansion pushing forward several initiatives and launching new products like the Volt plating systems for radius, humerus, and Rybrevant for EGFR-mutated non-small cell lung cancer. Several investment groups have increased or decreased their holdings in JNJ indicating uncertainty. The company has made strides in innovation recognized by being named in Fortune's 2025 America’s Most Innovative Companies list and advise for continued payout marking it a Top Pick for Down Markets. JNJ is also making efforts in promoting healthcare globally, evidenced by its participation in the World Health Organization's (WHO) Academy. However, despite advancements in cancer treatment and global health initiatives, the company faces criticism and market drops due to their ongoing legal issues and tariff issues.
Johnson Johnson JNJ News Analytics from Wed, 25 Sep 2024 07:00:00 GMT to Sat, 21 Jun 2025 09:20:59 GMT -
Rating 0
- Innovation 5
- Information 6
- Rumor -2
